-

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings.

Forte’s CEO, Paul Wagner, PhD will be presenting at the Guggenheim Emerging Outlook: Biotech Summit at 8:30 am ET on February 11th hosted at the Lotte New York Palace in New York, NY.

Additionally, on March 4th at 1:50 pm ET, Dr. Wagner will be presenting at the TD Cowen 46th Annual Healthcare Conference hosted at the Boston Marriot Copley Place in Boston, MA.

March 10-12, Dr. Wagner will be attending the Barclays 28th Annual Global Healthcare Conference hosted at the Loews Miami Beach Hotel in Miami Beach, FL.

About Forte

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.

Source: Forte Biosciences, Inc.

Contacts

LifeSci Advisors
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com

Industry:

Forte Biosciences, Inc.

NASDAQ:FBRX
Release Versions
English

Contacts

LifeSci Advisors
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com

More News From Forte Biosciences, Inc.

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s Board of Directors approved the grant of equity awards in the form of options to purchase a total of 50,000 shares of its c...

Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its first quarter 2026 financial results and provided a business update. “FB102 received Fast Track Designation from the FDA in celiac disease, highlighting the unmet need and reinforcing FB102’s potential to address the high unmet need in celiac disease. The clinical development for FB102 continue...

Forte Biosciences Announces Pricing of $150 Million Public Offering

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,709,936 shares of its common stock at a price to the public of $26.27 per share. In addition, Forte has granted the underwriters a 30-day option to purchase up to an additional 856,490 shares of its common stock at the public offering price, less the underwriting discounts and comm...
Back to Newsroom